

Tecan appoints Martin Brusdeilins as Chief Scientific Officer and Member of the Group Management Board

- **Martin Brusdeilins' extensive international experience in Research & Development to strengthen the Group Management Board**
- **Science & Technology organizational unit to play a decisive role in the implementation of the growth strategy**

Männedorf, Switzerland, July 4, 2011 – The Board of Directors of the Tecan Group (SIX Swiss Exchange: TECN) has appointed Dr. Martin Brusdeilins as Chief Scientific Officer and a Member of the Group Management Board. He will head the new Science & Technology organizational unit at Group level and take up his role at Tecan on September 1, 2011.

Tecan CEO Thomas Bachmann commented: "We are very pleased to have Martin Brusdeilins, with his extensive experience, on board as Chief Scientific Officer to help shape the future development of Tecan. His expertise and his international network of contacts will benefit both our end customers and our OEM business. As Head of the Science & Technology organizational unit, Martin Brusdeilins will play a decisive role in our new Group organization. By bundling our knowledge resources, we aim to further strengthen the focus on integrated workflow solutions and speed up the pace of innovation – an essential factor in the further implementation of our growth strategy."

Dr. Martin Brusdeilins has extensive experience in a variety of management positions in the diagnostic and life science industry. He worked at Ortho-Clinical Diagnostics Inc., an enterprise of the Johnson & Johnson Company in Rochester, New York, USA, from 2003 until the end of May 2011, latterly as Vice President Product Development. In this role and in his previous role as Vice President Research & Development, which he performed for over six years, he was responsible for global product development of all diagnostic instruments and reagents as well as the life cycle management of these products. From 1985 to 2003, Martin Brusdeilins held various management and professional positions at Roche Diagnostics in Europe and the USA, where he was responsible for the entire product development of near patient diagnostic tests and test instruments, including in his role as Vice President Research & Development Near Patient Testing. From 1998 to 2001, as Vice President and General Manager, he was responsible for production, research & development, marketing and quality assurance, and clinical studies in a business unit of Roche Diagnostics in the USA.

Martin Brusdeilins studied biochemistry at the Eberhard Karls Universität Tübingen and earned a doctorate in this subject at the Max Planck Institute for Biology in Tübingen, Germany. He is 59 years old and a German citizen.



2

The Science & Technology organizational unit was created as part of the new Group organization that became effective in 2011, with the aim of implementing Tecan's growth strategy even more effectively. The new structure aims to drive forward the development of integrated workflow solutions, to better leverage synergies in the development of technology, and to further accelerate the pace of innovation. Science & Technology bundles resources for the development of enabling technologies, for licensing, and for scouting of technologies. It is also responsible for evaluating the content of the technologies in M&A projects and for developing partnerships with industry and academic research. The organizational unit incorporates the Innovation & Incubation group, which will continue in its role.

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2010, Tecan generated sales of CHF 371 million (USD 356 million; EUR 269 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN: 12100191).

For further information:

Tecan Group

Martin Brändle

Head of Corporate Communications & Investor Relations

Tel. +41 (0) 44 922 84 30

Fax +41 (0) 44 922 88 89

investor@tecan.com

www.tecan.com